“ From an R&D perspective ... what is critical in ophthalmology is the development of a novel drug delivery mechanism ”
In Conversation
“ Despite being a relatively new company, in 2019, we raised the most money in our field in China. We are really one of the frontrunners in… ”
“ It is lamentable that some of the lessons of the previous H1N1 pandemic were forgotten as the world tried to cope with the COVID-19 outbreak. In… ”
“ Fundamentally, we need to keep an open mind about learning from existing models, yet should avoid simply copying and pasting what has worked in other countries… ”
“ JLABS @ Shanghai is a no-strings-attached incubator, which means entrepreneurs are free to develop their science while holding on to their intellectual property - providing a… ”
“ The core business – our research-driven, data-driven approach to innovation – has not changed [post-IPO]. We are committed to developing our portfolio and generating value for… ”
“ Before the IPO, we might have been seen as a mostly Chinese company working on interesting science and products, but now we are evidently a globally-ready… ”
“ From the time of Harbour BioMed’s inception in 2016, we have always set out to be a patient-centric global biotech company with multiple forms of value… ”
“ Even though lab animals make up only a limited portion of the total cost of new drug development, they are very important for every R&D process… ”
“ I am at a stage where I have a different perspective, which allows me to conduct R&D in a different way - doing disruptive innovation ”
“ The current hot topic is China’s focus on ensuring that healthcare innovation does not only depend on foreign innovation but how it can be translated and… ”
“ Our animal facility is the first one in China to earn AAALAC accreditation and has maintained it for 13 years. We adhere to strict international standards. Our… ”
